Buscar
Theratechnologies Inc
THTXAñadir a la lista de seguimiento
3.390USD
0.0000.00%
Cierre 07/02, 13:00（ET）Cotizaciones retrasadas 15 min
155.87MCap. mercado
PérdidaP/E TTM
Más Datos de Theratechnologies Inc Compañía
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.
Información de Theratechnologies Inc
Símbolo de cotizaciónTHTX
Nombre de la empresaTheratechnologies Inc
Fecha de salida a bolsaDec 21, 1993
Director ejecutivoMr. Paul Levesque
Número de empleados94
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 21
Dirección2015 Peel Street, 11th Floor
CiudadMONTREAL
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísCanada
Código postalH3A 1T8
Teléfono15143367800
Sitio Webhttps://www.theratech.com/
Símbolo de cotizaciónTHTX
Fecha de salida a bolsaDec 21, 1993
Director ejecutivoMr. Paul Levesque
Ejecutivos de Theratechnologies Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jocelyn Lafond
Mr. Jocelyn Lafond
General Counsel, Company Secretary
General Counsel, Company Secretary
--
-100.00%
Mr. Joseph P. Arena
Mr. Joseph P. Arena
Independent Director
Independent Director
--
--
Mr. John Leasure
Mr. John Leasure
Global Commercial Officer
Global Commercial Officer
--
-100.00%
Mr. Paul Levesque
Mr. Paul Levesque
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
-100.00%
Mr. Frank A. Holler
Mr. Frank A. Holler
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
-100.00%
Dr. Christian Marsolais, Ph.D.
Dr. Christian Marsolais, Ph.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
--
-100.00%
Ms. Dale Maccandlish Weil
Ms. Dale Maccandlish Weil
Independent Director
Independent Director
--
-100.00%
Mr. Andre Dupras
Mr. Andre Dupras
Vice President of Human Resources
Vice President of Human Resources
--
--
Ms. Elina Tea
Ms. Elina Tea
Independent Director
Independent Director
--
--
Mr. Andrew Thomas Molson
Mr. Andrew Thomas Molson
Independent Director
Independent Director
--
-100.00%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jocelyn Lafond
Mr. Jocelyn Lafond
General Counsel, Company Secretary
General Counsel, Company Secretary
--
-100.00%
Mr. Joseph P. Arena
Mr. Joseph P. Arena
Independent Director
Independent Director
--
--
Mr. John Leasure
Mr. John Leasure
Global Commercial Officer
Global Commercial Officer
--
-100.00%
Mr. Paul Levesque
Mr. Paul Levesque
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
-100.00%
Mr. Frank A. Holler
Mr. Frank A. Holler
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
-100.00%
Dr. Christian Marsolais, Ph.D.
Dr. Christian Marsolais, Ph.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
--
-100.00%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Theratechnologies Inc?
Los cinco principales accionistas de Theratechnologies Inc son: Mr. Jocelyn Lafond
¿Cuántas instituciones poseen acciones de Theratechnologies Inc (THTX)?
A fecha de 2026Q1, 78 instituciones poseen acciones de Theratechnologies Inc, con un valor de mercado combinado de aproximadamente 293.53K, lo que representa el 0.64% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -22862543.00.
¿Cuál es la mayor fuente de ganancias de Theratechnologies Inc?
El 2026Q1, el segmento empresarial EGRIFTA generó la ganancia más alta para Theratechnologies Inc, ascendiendo a 11.13M y representando el 62.78% de la ganancia total.